Kurma Partners Biofund IV

About Kurma Partners Biofund IV

Kurma Partners closes €215M Biofund IV, crossing €1B AUM on back of four big pharma exits. Invests in European biotech and biopharma companies at Series A and B stages.

Investment Focus

Location / RegionFrance

Funding StageSeries A

Industry Focus

Biotech

Therapeutics

Investor Signals Profile

active

Sweet Spot

Scientific founder or academic researcher in European therapeutics targeting severe or rare disease

biotech-early-stage

company-creation

rare-disease

therapeutics

academic-spinouts

Bullish Signals

Four Big Pharma exits in single fund cycle — AZ, Lilly, uniQure, Ipsenblog

CSL cornerstone LP signals privileged pharma BD access for portfolio companiesblog

11 investments already made, 9 more planned with capital actively deployingblog

Crossed €1B AUM enabling co-lead roles on larger European roundsblog

Paris HQ — 24 Rue Royale, prime location confirmedlinkedin

Website active — kurmapartners.com operationallinkedin

Contrarian Signals

Fund closed €35M below €250M target — LP appetite had limitsblog

Company-creation model is slower — 10-12 year timeline to exitblog

80% therapeutics concentration creates binary clinical outcome riskblog

11-50 staff — lean team for active portfolio sizelinkedin

Founder Do's

Engage Kurma before forming a legal entity if you have academic IP

Focus pitch on severe or rare diseases with high unmet medical need

Highlight scientific depth and academic institution partnerships

Demonstrate readiness for long-term pharma BD conversations

Position your program for eventual Big Pharma trade sale

Founder Don'ts

Pitch non-therapeutic plays — 80% focus is therapeutics only

Expect purely financial partnership — they are deeply hands-on operationally

Come without strong scientific credentials or life sciences background

Key GPs & Partners

Jacques Chatain

Directeur Général / Founder

ex-founderthesis-drivencommunity-builder

Jim Cowart

Managing Partner

hands-onmetrics-driventhesis-driven

Hadrien Bouchez

Partner

thesis-driven

Daniel Parera

Principal

metrics-driven

Unlock Investor Signals

$29/month for full signal access. Cancel anytime.

View Plans Browse all Signal Profiles →

Fund Overview

Fund Size€215M

Saves0

Website

Key People

Vanessa Malier

Jacques ChatainDirecteur Général / Founder

Jim CowartManaging Partner

Hadrien BouchezPartner

Daniel PareraPrincipal